Objective: To investigate the effects of oxcarbazepine on immune function, thyroid function and related factors in epilepsy patients. Method: 90 patients with epilepsy who visited our hospital from January 2015 to May...Objective: To investigate the effects of oxcarbazepine on immune function, thyroid function and related factors in epilepsy patients. Method: 90 patients with epilepsy who visited our hospital from January 2015 to May 2018 were selected as the observation group and 90 healthy volunteers were selected as control group. All patients in the observation group were treated with oxcarbazepine alone. T lymphocyte subsets, IgA, IgG, IgM, T3, T4, FT3, FT4, TSH, hs-CRP and Hcy in observation group were detected before treatment, 3 months after treatment and 6 months after treatment. The results were compared with those of the control group. Results: The levels of CD3+ and CD4+ in the control group were (65.25±9.51)% and (43.29±6.74)% respectively, which were higher than those in the observation group (P<0.05). The levels of CD8+, IgA and IgG in the control group were (22.40±6.41)%, (2.22±0.51) g/L, (9.99±1.28) g/L respectively, which were lower than those in the observation group (P<0.05). The levels of CD3+ and CD4+ in the observation group after 3 months and 6 months of treatment were significantly higher than those before treatment (P<0.05). The levels of CD8+, IgA and IgG in the observation group after 3 months and 6 months of treatment were significantly lower than those before treatment (P<0.05). There was no significant difference in the level of IgM between the observation group and the control group at each time point (P>0.05). The levels of thyroid hormones in the observation group before treatment and 3 months after treatment were not significantly different from those in the control group (P>0.05). The FT4 of the observation group was (14.98±1.03) pmol/L 6 months after treatment, which was significantly lower than that of the control group before treatment and 3 months after treatment (P<0.05). The levels of T3, T4, FT3 and TSH at each time point in the observation group were not significantly different from those in the control group (P>0.05). Before treatment, there was no significant difference in hs-CRP and Hcy levels between the observation group and the control group (P>0.05). The levels of hs-CRP and Hcy in the observation group were (4.82±0.67) mg/L and (13.36±1.51) umol/L respectively after 3 months of treatment. The levels of hs-CRP and Hcy in the observation group after 3 months of treatment were significantly higher than those before treatment and in the control group, and the difference was statistically significant (P<0.05). The levels of hs-CRP and Hcy in the observation group were (4.99±0.47) mg/L and (16.83±1.94) umol/L respectively after 6 months of treatment. The levels of hs-CRP and Hcy in the observation group were significantly higher than those in the control group after 3 months of treatment and before treatment (P<0.05). Conclusion: Oxcarbazepine can effectively improve the immune function of epilepsy patients, but with the prolongation of medication time, it may have adverse effects on thyroid function, hs-CRP and Hcy.展开更多
文摘Objective: To investigate the effects of oxcarbazepine on immune function, thyroid function and related factors in epilepsy patients. Method: 90 patients with epilepsy who visited our hospital from January 2015 to May 2018 were selected as the observation group and 90 healthy volunteers were selected as control group. All patients in the observation group were treated with oxcarbazepine alone. T lymphocyte subsets, IgA, IgG, IgM, T3, T4, FT3, FT4, TSH, hs-CRP and Hcy in observation group were detected before treatment, 3 months after treatment and 6 months after treatment. The results were compared with those of the control group. Results: The levels of CD3+ and CD4+ in the control group were (65.25±9.51)% and (43.29±6.74)% respectively, which were higher than those in the observation group (P<0.05). The levels of CD8+, IgA and IgG in the control group were (22.40±6.41)%, (2.22±0.51) g/L, (9.99±1.28) g/L respectively, which were lower than those in the observation group (P<0.05). The levels of CD3+ and CD4+ in the observation group after 3 months and 6 months of treatment were significantly higher than those before treatment (P<0.05). The levels of CD8+, IgA and IgG in the observation group after 3 months and 6 months of treatment were significantly lower than those before treatment (P<0.05). There was no significant difference in the level of IgM between the observation group and the control group at each time point (P>0.05). The levels of thyroid hormones in the observation group before treatment and 3 months after treatment were not significantly different from those in the control group (P>0.05). The FT4 of the observation group was (14.98±1.03) pmol/L 6 months after treatment, which was significantly lower than that of the control group before treatment and 3 months after treatment (P<0.05). The levels of T3, T4, FT3 and TSH at each time point in the observation group were not significantly different from those in the control group (P>0.05). Before treatment, there was no significant difference in hs-CRP and Hcy levels between the observation group and the control group (P>0.05). The levels of hs-CRP and Hcy in the observation group were (4.82±0.67) mg/L and (13.36±1.51) umol/L respectively after 3 months of treatment. The levels of hs-CRP and Hcy in the observation group after 3 months of treatment were significantly higher than those before treatment and in the control group, and the difference was statistically significant (P<0.05). The levels of hs-CRP and Hcy in the observation group were (4.99±0.47) mg/L and (16.83±1.94) umol/L respectively after 6 months of treatment. The levels of hs-CRP and Hcy in the observation group were significantly higher than those in the control group after 3 months of treatment and before treatment (P<0.05). Conclusion: Oxcarbazepine can effectively improve the immune function of epilepsy patients, but with the prolongation of medication time, it may have adverse effects on thyroid function, hs-CRP and Hcy.
